OTCMKTS:SKBI - Skystar Bio-Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0001
Today's RangeN/A
52-Week Range$0.0001 - $0.06
Volume547 shs
Average Volume186 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-24.9
Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People's Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi'an, the People's Republic of China.

Receive SKBI News and Ratings via Email

Sign-up to receive the latest news and ratings for SKBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:SKBI
CUSIPN/A
Phone86-29-8819-3188

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares8,700,000
Market Cap$0.00

The Truth About Cryptocurrencies

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Frequently Asked Questions

What is Skystar Bio-Pharmaceutical's stock symbol?

Skystar Bio-Pharmaceutical trades on the OTCMKTS under the ticker symbol "SKBI."

What is the consensus analysts' recommendation for Skystar Bio-Pharmaceutical?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Skystar Bio-Pharmaceutical in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Skystar Bio-Pharmaceutical's key competitors?

Who are Skystar Bio-Pharmaceutical's key executives?

Skystar Bio-Pharmaceutical's management team includes the folowing people:
  • Mr. Weibing Lu, Chairman and Chief Exec. Officer (Age 55)

Has Skystar Bio-Pharmaceutical been receiving favorable news coverage?

Media headlines about SKBI stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Skystar Bio-Pharmaceutical earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news coverage about the healthcare company an impact score of 47.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Skystar Bio-Pharmaceutical?

Shares of SKBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Skystar Bio-Pharmaceutical?

Skystar Bio-Pharmaceutical's mailing address is RM 10601 JIEZUO PLAZA NO. 4 FENGHUI ROAD SOUTH, XIAN F4, . The healthcare company can be reached via phone at 86-29-8819-3188 or via email at [email protected]


MarketBeat Community Rating for Skystar Bio-Pharmaceutical (OTCMKTS SKBI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Skystar Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe SKBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.